- $2.36m
- -$0.96m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.68 | ||
| Price to Tang. Book | 0.68 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -121.1% | ||
| Return on Equity | -229.26% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Directors
- Don Hankey CHM (77)
- Jeffrey Frelick PRE (55)
- Deina Walsh CFO (56)
- Bret Hankey DRC (43)
- Stephen La Neve DRC (61)
- Bruce Stroever DRC (70)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 18th, 2007
- Public Since
- November 27th, 2015
- No. of Shareholders
- 22
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 3,271,042
- Address
- 2 Burlington Woods Dr Ste 100, BURLINGTON, 01803-4551
- Web
- https://www.bonebiologics.com/
- Phone
- +1 7815524452
- Contact
- Kim Golodetz
- Auditors
- WEINBERG & COMPANY PA
Upcoming Events for BBLG
Bone Biologics Corp Annual Shareholders Meeting
Q2 2025 Bone Biologics Corp Earnings Release
Bone Biologics Corp Annual Shareholders Meeting
Similar to BBLG
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Bone Biologics share price?
As of Today at 19:40 UTC, shares in Bone Biologics are trading at $0.72. This share price information is delayed by 15 minutes.
How has the Bone Biologics share price performed this year?
Shares in Bone Biologics last closed at $0.72 and the price had moved by -60.89% over the past 365 days. In terms of relative price strength the Bone Biologics share price has underperformed the S&P500 Index by -64.73% over the past year.
What are the analyst and broker recommendations for Bone Biologics?
The overall consensus recommendation for Bone Biologics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Bone Biologics dividend yield?
Bone Biologics does not currently pay a dividend.
Does Bone Biologics pay a dividend?
Bone Biologics does not currently pay a dividend.
When does Bone Biologics next pay dividends?
Bone Biologics does not currently pay a dividend.
How do I buy Bone Biologics shares?
To buy shares in Bone Biologics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bone Biologics?
As of the previous close price of $0.72, shares in Bone Biologics had a market capitalisation of $2.36m.
Where are Bone Biologics shares listed?
Here are the trading details for Bone Biologics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BBLG
What kind of share is Bone Biologics?
Based on an overall assessment of its quality, value and momentum Bone Biologics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bone Biologics share price forecast for 2025?
The analyst consensus target price for shares in Bone Biologics is $16.50. That is 2183.74% above the last closing price of $0.72.
Analysts covering Bone Biologics currently have a consensus Earnings Per Share (EPS) forecast of -$1.95 for the next financial year.
Find out moreWhat is the trend in the Bone Biologics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bone Biologics. Over the past six months, its share price has underperformed the S&P500 Index by -44.17%.
As of the last closing price of $0.72, shares in Bone Biologics were trading -42.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bone Biologics PE Ratio?
The Bone Biologics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.72.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bone Biologics?
Bone Biologics' management team is headed by:
- Don Hankey - CHM
- Jeffrey Frelick - PRE
- Deina Walsh - CFO
- Bret Hankey - DRC
- Stephen La Neve - DRC
- Bruce Stroever - DRC